3
Announcements
Trials
Browse
Landscape
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
17
Lung Neoplasms
5
Ovarian Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Esophageal Neoplasms
3
Stomach Neoplasms
2
Retinoblastoma
2
Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous-Cell Lung Cancer
1
Retinal Neoplasms
1
Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)
1
Resectable Non-small Cell Lung Cancer
1
Resectable Lung Non-Small Cell Carcinoma
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Cancer Recurrent
1
Oropharyngeal Neoplasms
1
NSCLC
1
Lymphatic Metastasis
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Gallbladder Neoplasms
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Bronchogenic
1
Carcinoma
1
Interventions
Gemcitabine
39
Cisplatin
24
Oxaliplatin
21
Capecitabine
20
Fluorouracil
11
Leucovorin
9
Irinotecan
9
130-nm albumin-bound paclitaxel
8
durvalumab
6
Taxes
5
Radiotherapy
5
Platinum
4
Immunohistochemistry
4
Erlotinib Hydrochloride
4
Docetaxel
4
Carboplatin
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
1,2-diaminocyclohexaneplatinum II citrate
4
trifluridine tipiracil drug combination
3
Trastuzumab
3
Sorafenib
3
Observation
3
Epirubicin
3
Drug Therapy
3
tremelimumab
2
toripalimab
2
regorafenib
2
pembrolizumab
2
anlotinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Gallbladder Neoplasms
×
Platinum Compounds
×
Clear all
NCT03668418
2018-09-12
xenoZ
University of Pisa
Unknown
120 enrolled